Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients -- Company gains NIH Fast-Track award ...
NIH funding supports a clinical trial of Storii’s telephone-based memoir service that reduces isolation, improves mental health, and connects rural older adults With just a telephone call, we’re ...
What is the effectiveness of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health (NIH)? An ad hoc committee will ...
Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics targeting Alzheimer’s (AD) and rare neurodegenerative diseases, announced an ...
Continued organic quarter over quarter revenue growth despite expected summer seasonalityEarnings per share for Q3, 2025: ($0 ...
Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management teamHOUSTON, Dec.
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance ...
RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback